anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Participants receive a placebo supplement at the first study session (Aspartame sweetener mixed with water + aspartame capsule), then the next session they receive the dietary supplement (10g Fibersol®-2 mixed with water and aspartame sweetener + 725mg decaffeinated green tea extract capsule). Participants will also receive a drink containing alcohol (vodka + cranberry mixer) on both sessions.
There is a large body of literature hinting at a role of the gut in Type One Diabetes (T1D) pathogenesis. However, to the best of our knowledge there is no definitive evidence to date conclusively demonstrating a link. The only way to test this hypothesis is to have access to the intestinal tissue of T1D patients at very early stages when beta-islet cell destruction is still ongoing. Furthermore, to prepare for large prospective studies it is critical to determine whether there is a peripheral blood signature for intestinal inflammation. Finally, because enteroviral infections have been implicated in T1D pathogenesis, this study provides a unique opportunity to determine whether there is a dysregulated response to innate stimuli associated with viral infections and whether evidence of transcriptional signatures indicative of viral infections in the gut is correlated with disease. Finally, we will take advantage of this pilot study to collect samples that can be used for microbiome, virome and metabolic studies.
Moderate intensity exercise training will be a 12-week supervised cycling program, with supervision directly from our research team. All participants will first receive a one-on-one orientation with an exercise training specialist that has been trained by Dr. Gary Pierce in monitoring an exercise program for healthy older adults. Training will start with a 5 minute-warm-up, 20 minutes moderate intensity cycling and 30 minutes passive cycling, and 5 minute cool-down per session, for 3 sessions/week. In each additional week, we will add 6 minutes of moderate intensity cycling per session, until the total time for moderate intensity is 50 minutes per session by the start of week 5 (with additional 5 minute warm-up and 5 minute cool-down).
Intake of Gabbroral® oral tablet formulation, which will be dissolved in a glas of 240mL water, in fasted state. Fasted state means that you have eaten nothing for 12 hours for the investigation and only have been drinking water. • After intake of the medicine at regular intervals, gastrointestinal fluids will be aspirated over 4 hours. You sit in a comfortable position in bed; eating and sleeping is not permitted (after 2 hours you have the possibility to drink some water). After 4 hours, the gastrointestinal catheters will be removed and you may eat and roam freely.
This will be a 2 parallel group multicentre randomised controlled trial. Patients will undergo 3 consultations with the physician, based on the usual follow up for this pathology. During the first consultation the physician will check the inclusion criteria, medical history, clinical data relative to the different outcomes, and prescribe optimizated pain killers and deliver information about self care and physical activity. Patient reported outcome measures will be assessed through self answering questionnaires with the help of a research assistant if necessary. After randomisation the prosthetist will take the measurement to conceive the custom brace. Patients will then be re-examined during a 2nd consultation 3 month later to assess the main outcome (pain reduction) and other secondary outcome (proms). A third consultation will be organised 6 months later for secondary outcome (pain reduction and proms).
INTRODUCTION AND HYPOTHESIS: We describe the surgical management of intravesical mesh perforation following transvaginal mesh surgery for pelvic organ prolapse.
METHODS: A 73-year-old woman presented with intravesical mesh perforation 17 years following transvaginal mesh-based prolapse repair at an outside hospital. The patient presented with intermittent hematuria and recurrent urinary tract infections. Cystoscopy demonstrated an approximately 3-cm area of intravesical mesh with associated stone spanning from the bladder neck through the left trigone and ureteral orifice. A robotic-assisted transvesical mesh excision and left ureteroneocystostomy was carried out. Robotic-assisted repair was performed transvesically via transverse bladder dome cystotomy. Dissection was carried out circumferentially around the mesh in the vesicovaginal plane, including a 1-cm margin of healthy tissue. The eroded mesh was excised, and the vaginal wall and bladder were closed with running absorbable sutures. Given the location of the mesh excision and repair, a left ureteral reimplantation was performed. The transverse cystotomy was closed and retrograde bladder filling with methylene blue-stained saline confirmed watertight repairs, with no vaginal extravasation.
RESULTS: The patient was discharged the following morning and had an uneventful recovery, including transurethral indwelling catheter removal at 2 weeks after CT cystogram and subsequent ureteral stent removal at 6 weeks postoperatively. At 2-month follow-up she had no new urinary symptoms or obstruction of the ureteral reimplantation on renal ultrasound.
CONCLUSIONS: A robotic-assisted approach is a feasible option for managing transvaginal prolapse mesh perforation into the bladder. Pelvic surgeons must be well equipped to handle transvaginal mesh complications in a patient-specific manner.
FIELD: ophthalmological oncology. SUBSTANCE: recombinant interleukin-2 (Ronkoleukin) is injected intravenously in dropwise manner in dose 1-1.5 mln Un. , 5 infusions in one course. If regression of tumor and/or metastases is insufficient, the courses are repeated. EFFECT: enabled destruction or diminishing of dimensions of primary or and/or metastatic tumor nodule up to complete regression allowing preservation of eye as organ. 2 cl, 2 ex
This study longitudinally evaluated the immune response in individuals over a year after receiving three doses of an inactivated SARS-CoV-2 vaccine, focusing on reactions to Omicron breakthrough infections. From 63 blood samples of 37 subjects, results showed that the third booster enhanced the antibody response against Alpha, Beta, and Delta VOCs but was less effective against Omicron. Although antibody titres decreased post-vaccination, SARS-CoV-2-specific T-cell responses, both CD4+ and CD8+, remained stable. Omicron breakthrough infections significantly improved neutralization against various VOCs, including Omicron. However, the boost in antibodies against WT, Alpha, Beta, and Delta variants was more pronounced. Regarding T cells, breakthrough infection predominantly boosted the CD8+ T-cell response, and the intensity of the spike protein-specific T-cell response was roughly comparable between WT and Omicron BA.5.
A method for production of porous hollow polymer fiber membranes. A homogeneous mixture is prepared from at least two components where one component is a fusible polymer (10 to 30 percent) and a solvent component (70-90%) is inert relative to the polymer and where said components form a binary system having in the liquid state a region of complete miscibility as well as a miscibility gap. The mixture is extruded at a temperature above the phase segregation temperature of the mixture through a hollow fiber nozzle into a spinning tube containing a solvent inert to the polymer and having a temperature below the segregation temperature. Fiber and liquid are moved in the spinning tube in the same direction at about the same speed. After solidification the hollow fiber membrane is washed with a solvent. A liquid mixture containing biological cells and macromolecules is passed through the membrane produced for filtration and a filtration factor for human blood proteins with molecular weights of from about 60,000 to 3 million results of at least about 0.7.
Effective treatment for recurrent gliomas is still challenging. Malignant gliomas are considered to be one of the most angiogenic cancers and are mostly sustained by vascular endothelial growth factor (VEGF) signaling via its endothelial tyrosine kinase receptor VEGF receptor 2 (VEGFR-2). Apatinib, also known as YN968D1, is a small-molecule tyrosine kinase inhibitor (TKI) that selectively binds to and inhibits VEGFR-2. Apatinib has been demonstrated as monotherapy that prolongs OS in patients with gastric cancers after two or more lines of chemotherapy with moderate, reversible, and easily managed adverse effects. This study aims to collect clinical, radiological and histopathology imaging including detailed radiological data, survival data, clinical parameters, molecular pathology and images of HE slices in patients with recurrent gliomas whose are treated with Apatinib, for evaluating the efficacy and safety of Apatinib. Moreover, by leveraging artificial intelligence, this study also seeks to construct and refine MR and histopathology imaging based algorithms that are able to predict the responses to Apatinib of patients with recurrent gliomas. The creation of a registry for patients with recurrent gliomas treated by Apatinib with detailed survival data, radiological data, histopathology image data and with sufficient sample size for artificial intelligence provides opportunities for personalized prediction of responses to Apatinib.
PURPOSE: The pudendal nerve is an anatomical structure arising from the ventral branches of the spinal roots S2-S4. Its complex course may be affected by surrounding structures. This may result in irritation or entrapment of the nerve with subsequent clinical symptoms. Aim of this study is to review the anatomy of the pudendal nerve and to provide detailed photographic documentation of the areas with most frequent clinical impact which are essential for surgical approach.
METHODS: Major medical databases were searched to identify all anatomical studies investigating pudendal nerve and its variability, and possible clinical outcome of these variants. Extracted data consisted of morphometric parameters, arrangement of the pudendal nerve at the level of roots, formation of pudendal nerve, position according to sacrospinal and sacrotuberal ligaments and its terminal branches. One female cadaver hemipelvis was dissected with common variability of separate course of inferior rectal nerve. During dissection photodocumentation was made to record course of pudendal nerve with focus on areas with recorded pathologies and areas exposed to iatrogenic damage during surgical procedures.
RESULTS: Narrative review was done to provide background for photodocumentation. Unique photos of course of the pudendal nerve was made in areas with great clinical significance.
CONCLUSION: Knowledge of anatomical variations and course of the pudendal nerve is important for examinations and surgical interventions. Surgically exposed areas may become a site for iatrogenic damage of pudendal nerve; therefore, unique picture was made to clarify topographic relations.
BACKGROUND: Individuals with obesity have higher level of circulating succinate, which acts as a signaling factor that initiates inflammation. It is obscure whether succinate and succinate receptor 1 (SUCNR1) are involved in the process of obesity aggravating acute lung injury (ALI).
METHODS: The lung tissue and blood samples from patients with obesity who underwent lung wedgectomy or segmental resection were collected. Six-week-old male C57BL/6J mice were fed a high-fat diet for 12 weeks to induce obesity and lipopolysaccharides (LPS) were injected intratracheally (100 μg, 1 mg/ml) for 24 h to establish an ALI model. The pulmonary SUCNR1 expression and succinate level were measured. Exogenous succinate was supplemented to assess whether succinate exacerbated the LPS-induced lung injury. We next examined the cellular localization of pulmonary SUCNR1. Furthermore, the role of the succinate-SUCNR1 pathway in LPS-induced inflammatory responses in MH-s macrophages and obese mice was investigated.
RESULT: The pulmonary SUCNR1 expression and serum succinate level were significantly increased in patients with obesity and in HFD mice. Exogenous succinate supplementation significantly increased the severity of ALI and inflammatory response. SUCNR1 was mainly expressed on lung macrophages. In LPS-stimulated MH-s cells, knockdown of SUCNR1 expression significantly inhibited pro-inflammatory cytokines' expression, the increase of hypoxia-inducible factor-1α (HIF-1α) expression, inhibitory κB-α (IκB-α) phosphorylation, p65 phosphorylation and p65 translocation to nucleus. In obese mice, SUCNR1 inhibition significantly alleviated LPS-induced lung injury and decreased the HIF-1α expression and IκB-α phosphorylation.
CONCLUSION: The high expression of pulmonary SUCNR1 and serum succinate accumulation at least partly participate in the process of obesity aggravating LPS-induced lung injury.
PROBLEM TO BE SOLVED: To prepare a cosmetic composition and a medicinal composition having antiallergic and antioxidant actions without any problems in safety. SOLUTION: The cosmetic composition and medicinal composition comprise an aqueous extract of Selaginella moellendorfii Hieron belonging to the genus Selaginella of the family Selaginellaceae or its fractionated substance alone or two or more thereof in combination as an active ingredient in an amount of 0.001-10wt.% in the total amount. The aqueous extract is obtained by extracting a fragment or a pulverized raw or dried root, leaf or stem part of Selaginella moellendorfii Hieron at ambient temperature to 100 deg.C for 1hr to 1 weak with water in an amount of 1-30 pts. based on 1 pt. root, leaf or stem part thereof. The fractionated substance is prepared by further partitioning the aqueous extract with a solvent and separating and fractionating the resultant fraction according to a chromatography.  A usually used ingredient can further suitably be blended therewith and prepared as a dentifrice, a mouthwash, a gel, an ointment, a lotion, a cosmetic oil, a cream, a milky lotion, a pack, a powder, a hair tonic, a shampoo, a rinse, a treatment, a mousse, a plaster, a juice, a candy, a chewing gum, a tablet, a troche, etc.
PCT No. PCT/FR95/01251 Sec. 371 Date Mar. 28, 1997 Sec. 102(e) Date Mar. 28, 1997 PCT Filed Sep. 28, 1995 PCT Pub. No. WO96/10043 PCT Pub. Date Apr. 4, 1996The invention relates to a functionalised polymer of formula:(P)-S-X-F(1)in which: (P) is a hydrophobic polymer chain obtained by radical polymerisation of at least one monomer, S represents sulphur, X represents: a saturated or unsaturated linear or branched hydrocarbon chain having 1 to 6 carbon atoms and substituted with at least one COOH or NH2 group in the free or salified form a peptide chain constituted of 2 to 4 amino acids, particularly natural amino acids, F represents a COOH or NH2 group, in the free or salified form, with the exception of the  omega -dicarboxylic macromonomers resulting from the radical polymerisation of a monomer in the presence of a chain transfer agent constituted of thiomalic acid. The invention also relates to the use of the above functionalised polymers as well as to those resulting from the radical polymerisation of a monomer in the presence of thiomalic acid, as surfactant especially as wetting agent, dispersing agent, stabilising agent of dispersion of particles or for preparing microdispersions. The invention also relates to cosmetic compositions including these polymers and especially nail varnishes.
The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings.

Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids (see DOSAGE AND ADMINISTRATION). 

Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees.

Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.
The present invention provides a separation method for dermatophagoides farinae allergy resistant active substance in propolis. The method comprises steps of: first, extracting the propolis with an ethanol solvent; second, conducting solid-liquid separation and rotary evaporation to remove ethanol, so as to obtain an extraction cream of dermatophagoides farinae allergy resistant active substance in propolis. According to the method, the extraction cream is further separated by column chromatography and thin layer chromatography to obtain active components. The method also comprises chemical structure identification on the active components of kaempferol and / or chrysin. The present invention provides a method for separating natural active substances from propolis and novel application of the active substances in resistance of dermatophagoides farinae allergy. The invention not only provides an efficient method and system for deep development and utilization of propolis, but also provides a new way for prophylaxis and treatment of dermatophagoides farinae allergen induced diseases.
Coronary artery disease is a leading cause of morbidity and mortality worldwide. It occurs due to a combination of genetics, lifestyle, and environmental factors. Premature coronary artery disease (PCAD) is a neglected clinical entity despite the rising number of cases worldwide. This study aimed to investigate the risk factors of premature coronary artery disease. In this study, we searched articles that had studied the risk factors of premature coronary artery diseases from January 2000 to July 2022 in Saudi Arabia in Web of Science, Pub Med, Scopus, Springer, and Wiley databases. The final analysis is based on seven articles. The smoking prevalence was 39%, diabetes mellitus 41%, hypertension 33%, overweight and obesity 18%, family history of coronary artery disease (CAD) 19%, dyslipidemia 37%, and the prevalence range of low-density lipoprotein cholesterol was 33.8-55.0%. The results revealed a mortality prevalence of 4% ranging from 2 to 8% which is similar to the prevalence in older patients which was 2-10%. Smoking, diabetes mellitus, hypertension, family history of CAD, dyslipidemia, and overweight/obesity are significantly and positively associated with premature coronary artery diseases. The health authorities should design and implement an intensive and effective prophylactic plan to minimize the subsequent impact of PCAD on the young population. In addition, early diagnosis of PCAD has great value in providing timely treatment, managing the patients, and minimizing the burden of the disease.
PURPOSE:To produce the titled active substance, by reacting an insoluble polymer having epoxy group with a specific monosaccharide or disaccharide under alkaline condition, oxidizing and breaking the reaction product with periodic acid, and reacting the resultant aldehyde group with a physiologically active substance having amino group, thereby immobilizing the substance. CONSTITUTION:An insoluble polymer having epoxy group (e.g. polyglycidyl methacrylate) is made to react, under alkaline condition, with a monosaccharide (e.g. glucose) or a disaccharide (e.g. lactose) having primary hydroxyl group and a diol group incisable by oxidation with periodic acid. The resultant sugar- bonded insoluble polymer is incised by oxidizing with periodic acid, and obtained aldehyde group is reacted with a physiologically active substance (e.g. protein) having amino group. If necessary, the immobilized product is reduced with sodium borohydride or sodium cyanoborohydride to stabilize the bond to obtain the objective immobilized physiologically active substance. The product has low non-specific adsorption of spacer, contains the introduced spacer having high chemical stabilty, gives high ligand concentration and has extremely high reaction yield of ligand.
OBJECTIVE: Functional dyspepsia (FD) is a gastrointestinal functional disorder of the upper gastrointestinal tract that affects the quality of life of patients and poses a significant economic burden. It has been proposed that the local inflammatory immune response at the duodenum is associated with an increase in intestinal permeability, favoring the recruitment of Th2 cells and granulocyte degranulation. Moreover, systemic immune response could also be related to the symptoms of FD. The objective of this study was to evaluate the systemic immune response in Uruguayan patients with FD by analyzing the cytokine levels in plasma and the frequency of circulating T cells associated with duodenal recruitment.
PATIENTS AND METHODS: An analytic and cross-sectional study in 30 patients with FD and 15 healthy controls (HCs) was carried out. Patients were diagnosed with FD according to the Roma IV Committee definition. Cytokine levels were measured in plasma by a specific assay. Expression of α4β7 and CC chemokine receptor9 in circulating T cells was evaluated by flow cytometry.
RESULTS: Higher levels of interleukin (IL)-5, IL-13, and IL-8 and lower levels of IL-10 and IL-12p70 were detected in patients with FD than in HC. Furthermore, a positive linear correlation between IL-13 and the severity of FD symptoms was found. CD4 + T cells from patients with FD expressed higher levels of α4β7 and CC chemokine receptor9 than those from HC.
CONCLUSIONS: An increase of Th2-like cytokines and a positive correlation between the levels of plasma IL-13 and the severity of symptoms in patients with FD from Uruguay were detected.
A topical hair care formulation and method of making includes combining herbal powders to form a herbal powder mixture. The herbal powder mixture is steeped in an amount of carrier oil for a period of time to form an infused oil. A portion of an amount of olive oil is combined with an amount of biotin and an amount of an organosulfur compound to form a natural mixture. A remainder of the amount of olive oil is combined with the infused oil. An amount of jojoba oil is combined with the infused oil. An amount of rosemary oil is combined with the infused oil. An amount of lavender oil is combined with the infused oil. The natural mixture is combined with the infused oil. The infused oil is settled for a period of time to form the topical hair care formulation.
If overdose occurs, the patient should be monitored for evidence of toxicity, and standard supportive treatment applied as necessary. Administration of activated charcoal may be used to aid removal of unabsorbed EFV. Hemodialysis can remove both FTC and TDF (refer to detailed information below) but is unlikely to significantly remove EFV from the blood.

Efavirenz: Some patients accidentally taking 600 mg twice daily have reported increased nervous system symptoms. One patient experienced involuntary muscle contractions.

Emtricitabine: Hemodialysis treatment removes approximately 30% of the FTC dose over a 3-hour dialysis period starting within 1.5 hours of FTC dosing (blood flow rate of 400 mL/min and a dialysate flow rate of 600 mL/min). It is not known whether FTC can be removed by peritoneal dialysis.

Tenofovir DF: Tenofovir is efficiently removed by hemodialysis with an extraction coefficient of approximately 54%. Following a single 300 mg dose of TDF, a 4-hour hemodialysis session removed approximately 10% of the administered tenofovir dose.